

Scott D Beattie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8478634/publications.pdf>

Version: 2024-02-01

19
papers

2,417
citations

777949

13
h-index

939365

18
g-index

20
all docs

20
docs citations

20
times ranked

2158
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. <i>Journal of Rheumatology</i> , 2022, 49, 133-141.	1.0	5
2	Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 568-582.	0.8	1
3	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 115.	1.6	11
4	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 887-895.	1.0	7
5	Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 14-21.	1.0	57
6	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662.	13.9	643
7	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.	2.9	42
8	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 88-95.	0.5	295
9	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	2.9	310
10	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	13.9	499
11	Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 333-340.	0.5	232
12	A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A31.2-A31.	0.5	8
13	Natural History of Cardiovascular Disease in Patients With Diabetes. <i>Diabetes Care</i> , 2008, 31, S155-S160.	4.3	118
14	Recruitment to a Clinical Trial Improves Glycemic Control in Patients With Diabetes. <i>Diabetes Care</i> , 2007, 30, 2989-2992.	4.3	41
15	Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 20-27.	1.2	16
16	Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D). <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 80-87.	1.2	28
17	Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?. <i>Diabetes Research and Clinical Practice</i> , 2003, 62, 187-195.	1.1	24
18	A Two-Stage Bayesian Model Selection Strategy for Supersaturated Designs. <i>Technometrics</i> , 2002, 44, 55-63.	1.3	77

#	ARTICLE	IF	CITATIONS
19	Use of insulin lispro (Humalog [®]) with CSII provides consistently better glyceic control than regular human insulin. <i>Diabetes Research and Clinical Practice</i> , 2000, 50, 221.	1.1	0